Results 181 to 190 of about 1,053,264 (360)

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

THE LIPID AND MINERAL DISTRIBUTION OF THE SERUM AND ERYTHROCYTES IN THE HEMOLYTIC AND HYPOCHROMIC ANEMIAS OF CHILDHOOD

open access: hybrid, 1937
Betty Nims Erickson   +4 more
openalex   +1 more source

RENAL FUNCTION DURING CHRONIC ANEMIA IN MAN [PDF]

open access: bronze, 1947
Stanley E. Bradley, Geraldine P. Bradley
openalex   +1 more source

Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. Methods This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies ...
Sílvia M. Illamola   +8 more
wiley   +1 more source

Prevalence and associated factors of anemia among newborns in Africa: a systematic review and meta-analysis. [PDF]

open access: yesBMC Pediatr
Messelu MA   +10 more
europepmc   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy